Gastroparesis Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2024-2028

#Snapshot img { margin: 10px !important; } Gastroparesis Drugs Market Size 2024-2028 The gastroparesis drugs market size is forecast to increase by USD 1.42 billion at a CAGR of 3.69% between 2024 and 2028.The market is witnessing significant growth due to the rising global burden of diabetes, a major cause of gastroparesis. Diabetes affects the nerves and muscles in the stomach, leading to delayed gastric emptying. According to the International Diabetes Federation, approximately 463 million adults were living with diabetes in 2019, and this number is projected to reach 700 million by 2045. Additionally, increasing growth opportunities in emerging markets and stringent regulatory guidelines are driving market growth.The market is expected to witness significant advancements with the development of novel therapeutic approaches, including botulinum toxin injections, electrical stimulation therapy, and probiotics. However, the high cost of treatment and the lack of reimbursement policies are major challenges limiting market growth. Overall, the market is expected to grow steadily during the forecast period, driven by the increasing prevalence of diabetes and the development of new therapeutic approaches.Gastroparesis Drugs Market Analysis Request Free SampleGastroparesis is a chronic gastrointestinal (GI) disorder characterized by delayed emptying of the stomach. Neurogastrx, a specialty pharmaceutical company, is developing Tradipitant, a selective 5-HT3 receptor antagonist, for the treatment of gastroparesis. Tradipitant has shown promise in clinical trials for improving GI symptoms such as nausea, vomiting, and digestive disruptions in patients with diabetes, lifestyle factors like alcohol consumption and tobacco use, and other underlying conditions. Other drugs used for gastroparesis include Metoclopramide, a prokinetic agent, and Domperidone, a motility agent. Evoke Pharma and Ani Pharmaceuticals are also developing innovative drugs for gastroparesis. However, the use of these drugs is not without risks, including liver injury, GI bleeding, acute cholecystitis, and acute pancreatitis.Antiemetics like Reglan and Erythromcin are sometimes used off-label for gastroparesis, but their long-term use can lead to serious side effects. The market for gastroparesis drugs is expected to grow due to the increasing prevalence of diabetes and other underlying conditions that contribute to the development of gastroparesis. The need for effective symptom management remains high, making the development of new and safer treatments a priority.How is this market segmented and which is the largest segment?The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.Drug ClassProkinetic agentsAntiemeticsBotulinum toxin injectionDisease TypeIdiopathic gastroparesisDiabetic gastroparesisPost-surgical gastroparesisGeographyNorth AmericaUSCanadaEuropeGermanyUKFranceItalyDenmarkNorwayAsiaIndiaChinaJapanSouth KoreaRest of World (ROW)By Drug Class InsightsThe Prokinetic agents segment is estimated to witness significant growth during the forecast period.Gastroparesis is a gastrointestinal disorder characterized by delayed stomach emptying, leading to various symptoms such as nausea, vomiting, abdominal discomfort, and bloating. Neurogastrx's tradipitant is a promising prokinetic drug under investigation for its potential in managing gastroparesis symptoms. Other prokinetic agents, including metoclopramide, domperidone, and deudomperidone, have been employed for decades to enhance gastric motility and alleviate gastroparesis symptoms. These medications, which also exhibit antiemetic properties, can help manage symptoms of gastroparesis caused by diabetes, lifestyles factors like alcohol consumption and tobacco use, autonomic neuropathy, and surgical procedures. Moreover, innovative drugs like ghrelin, motilin, 5-HT4 receptor agonists, and dopamine receptor agonists are being explored for their efficacy in treating gastroparesis.These drugs work by enhancing gastric motility, thereby aiding in blood sugar regulation and nutrient absorption. However, prokinetic agents may not always produce a corresponding change in stomach emptying to match the symptomatic response. Clinical trials and FDA clearance are crucial steps in bringing these drugs to market. For instance, Evoke Pharma's motilin receptor agonist, Amitiza, was approved by the FDA for treating chronic non-obstructive constipation, although its potential in gastroparesis treatment is being investigated. ANI Pharmaceuticals' domperidone is not yet approved in the US but is widely used in other countries for treating gastroparesis and other gastroin

胃轻瘫药物市场规模2024-2028年预测将增长14.2亿美元，年复合增长率达3.69%。市场增长显著，主要得益于全球糖尿病负担的加重，而糖尿病是胃轻瘫的主要诱因。糖尿病影响胃部的神经和肌肉，导致胃排空延迟。根据国际糖尿病联盟的数据，2019年约有4.63亿成年人患有糖尿病，预计到2045年这一数字将增至7亿。此外，新兴市场的增长机遇以及严格的监管指南也是推动市场增长的因素。随着新型治疗方法的开发，包括肉毒杆菌毒素注射、电刺激疗法和益生菌，市场预计将见证重大进展。然而，治疗成本高昂以及缺乏报销政策是限制市场增长的主要挑战。总体而言，预计在预测期内市场将稳步增长，由糖尿病的日益普遍和新疗法的开发所驱动。

胃轻瘫药物市场分析
请求免费样本
胃轻瘫是一种慢性胃肠道（GI）疾病，其特征为胃排空延迟。专注于特殊药品的Neurogastrx公司正在开发特拉皮坦，一种选择性5-HT3受体拮抗剂，用于治疗胃轻瘫。特拉皮坦在临床试验中显示出改善糖尿病、生活方式因素（如饮酒和吸烟）以及其他潜在疾病患者胃肠道症状（如恶心、呕吐和消化紊乱）的潜力。其他用于治疗胃轻瘫的药物包括促动力药甲氧氯普胺和促动力药多潘立酮。Evoke Pharma和Ani Pharmaceuticals也在开发针对胃轻瘫的创新药物。然而，这些药物的使用并非没有风险，包括肝损伤、胃肠道出血、急性胆囊炎和急性胰腺炎。抗恶心药如雷尼替丁和红霉素有时被非正式地用于治疗胃轻瘫，但长期使用可能导致严重副作用。由于糖尿病和其他导致胃轻瘫发展的潜在因素的日益普遍，以及有效症状管理的高需求，胃轻瘫药物市场预计将增长，使得开发新的、更安全的治疗方法成为当务之急。

如何对这个市场进行细分，哪个是最大的细分市场？
市场研究报告提供了全面的数据（按地区进行细分分析），包括2024-2028年的预测和估计（以亿美元为单位），以及2018-2022年的历史数据，以下为以下细分市场的数据。
药物类别
促动力药
止吐药
肉毒杆菌毒素注射
疾病类型
特发性胃轻瘫
糖尿病性胃轻瘫
术后胃轻瘫
地理
北美
美国
加拿大
欧洲
德国
英国
法国
意大利
丹麦
挪威
亚洲
印度
中国
日本
韩国
其他世界（ROW）
按药物类别洞察
预计在预测期内促动力药类别将见证显著增长。
胃轻瘫是一种以胃排空延迟为特征的胃肠道疾病，导致各种症状，如恶心、呕吐、腹部不适和腹胀。Neurogastrx的特拉皮坦是一种有潜力的促动力药物，正在研究其在管理胃轻瘫症状方面的潜力。其他促动力药物，包括甲氧氯普胺、多潘立酮和去甲氧氯普胺，已使用数十年，用于增强胃动力和缓解胃轻瘫症状。这些具有止吐特性的药物可以帮助管理由糖尿病、生活方式因素（如饮酒和吸烟）、自主神经病变和手术引起的胃轻瘫症状。此外，正在探索创新药物如生长素、促动力素、5-HT4受体激动剂和多巴胺受体激动剂在治疗胃轻瘫方面的疗效。
这些药物通过增强胃动力，从而有助于血糖调节和营养吸收。然而，促动力药物并不总是产生与症状反应相匹配的胃排空变化。临床试验和FDA批准是这些药物进入市场的重要步骤。例如，Evoke Pharma的促动力素受体激动剂Amitiza已获得FDA批准用于治疗慢性非梗阻性便秘，尽管其治疗胃轻瘫的潜力正在被研究。ANI Pharmaceuticals的甲氧氯普胺尚未在美国获得批准，但在其他国家广泛用于治疗胃轻瘫和其他胃肠道疾病。